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Risk Factors for Metabolic Syndrome
Independently Predict Arterial Stiffness
and Endothelial Dysfunction in Patients
With Chronic Kidney Disease and
Minimal Comorbidity
PAJAREE LILITKARNTAKUL, MD1
NEERAJ DHAUN, MBCHB, PHD1,2
VANESSA MELVILLE, BSC1
DEBBIE KERR, BSC1
DAVID J. WEBB, MD, FRCP1
JANE GODDARD, MBCHB, PHD2
OBJECTIVEdMetabolic syndrome (MS) is common in patients with chronic kidney disease
(CKD), but its contribution to arterial stiffness and endothelial dysfunction in CKD is not well
deﬁned. We hypothesized that risk factors for MS would independently predict arterial stiffness
and endothelial dysfunction in CKD patients.
RESEARCH DESIGN AND METHODSdRisk factors for MS, carotid-femoral pulse
wave velocity (CF-PWV) and ﬂow-mediated dilation (FMD) as measures of arterial stiffness
and endothelial dysfunction, respectively, were assessed in 113 minimally comorbid CKD
patients and in 23 matched control subjects.
RESULTSdCF-PWV correlated with systolic blood pressure (SBP), waist circumference, and
plasma glucose (r2 = 0.25, 0.09, and 0.09; P, 0.01 for all). FMD correlated with SBP (r2 = 0.09;
P, 0.01) and waist circumference (r2 = 0.03; P, 0.05). CF-PWV increased progressively (r2 =
0.07; P, 0.01) with increasing number of risk factors for MS. In multiple linear regression, SBP
and waist circumference were independent determinants of CF-PWV, whereas only SBP pre-
dicted FMD.
CONCLUSIONSdThe number of MS risk factors is an important determinant of arterial
stiffness in CKD patients irrespective of the degree of renal impairment. Although BP remains the
major determinant of arterial stiffness and endothelial dysfunction, waist circumference inde-
pendently predicts arterial stiffness. MS risk factors, particularly abdominal girth, are potential
targets for future interventional studies in patients with CKD.
Diabetes Care 35:1774–1780, 2012
Chronic kidney disease (CKD) iscommon and associated with an in-creased risk of cardiovascular disease
(CVD) (1). Conventional (Framingham)
CVD risk factors, including high blood
pressure (BP), hypercholesterolemia, and
diabetes, all of which are common in
CKD patients, only partly explain the
high cardiovascular risk (2). CKD is now
regarded as an independent risk factor for
CVD (1,3), and we have recently shown
that renal dysfunction also contributes to
arterial stiffness and endothelial dysfunc-
tion in a group of minimally comorbid
CKD patients (4).
Increased arterial stiffness, as mea-
sured by pulse wave velocity (PWV), is a
commonly recognized feature ofCKD (4), a
marker of cardiovascular risk (5,6), and an
independent predictor of mortality and
survival in dialysis patients (6). The vascu-
lar endothelium is an important regulator
of arterial stiffness (7), and endothelial dys-
function is also a common feature of CKD
(8) and a predictor of CVD (9).
Metabolic syndrome (MS) is a clus-
tering of metabolic abnormalities and risk
factors for CVD and includes abdominal
obesity, hyperglycemia, hypertension,
hypertriglyceridemia, and reduced HDL
cholesterol (10). As MS is associated with
increased risks of diabetes and CVD
(11,12), its treatment and prevention
have become one of the major public
health challenges worldwide. The risk
factors for MS, either together or individ-
ually, are also associated with arterial stiff-
ness and endothelial dysfunction both in
health (13,14) and disease (15,16).
MS is widely prevalent in CKD (17)
and is itself a risk factor for CKD (18).
Although a recent study has suggested
that MS and its risk factors contribute to
arterial stiffness and endothelial dysfunc-
tion in dialysis patients (19), there are no
data relating to predialysis CKD. This is
clearly important because targeting MS
risk factors in early CKD may retard
CKD progression, delaying the onset of
dialysis and its associated morbidity, as
well as reducing the overall risk of CVD.
In this current study, we investigated
the relationships of MS and its individual
components to arterial stiffness and endo-
thelial dysfunction inCKDpatients across a
wide range of renal function from early
CKD topredialysis. Importantly,weplanned
to recruit patients without diabetes or car-
diovascular comorbidity.We hypothesized
that the presence ofMS, or its components,
would be associated with increased
arterial stiffness and endothelial dys-
function and that these relationships
would be independent of renal function
and other well-established risk factors for
CVD.
RESEARCH DESIGN AND
METHODSdThe rationale and study
design have been reported in detail else-
where (4). In brief, subjects were recruited
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from the renal outpatient clinic at the Royal
Inﬁrmary of Edinburgh. They were catego-
rized into the ﬁve stages of CKD on the
basis of the Kidney Disease OutcomeQual-
ity Initiative (K/DOQI) classiﬁcation (20).
Age-matched healthy volunteers were re-
cruited from the community as a control
group.
The inclusion criteria were as follows:
male or female CKD patients, 18–65 years
old, and clinic BP #160/100 mmHg,
whether or not on antihypertensive med-
ication.We excluded patients with a renal
transplant or on dialysis, systemic vascu-
litis or connective tissue disease, a history
of established CVD, peripheral vascular
disease, diabetes, respiratory or neuro-
logic disease, and current alcohol abuse
or pregnancy and those treated with an
organic nitrate or b-agonist. Patients con-
tinued their usual medications until the
study morning. Smokers and hypercho-
lesterolemic patients were not excluded,
but the latter had to be established on statin
medication, with good cholesterol control,
for at least 3 months before taking part in
the study.
Diagnosis of MS
MS was diagnosed according to the crite-
ria from the third report of the National
Cholesterol Education Program (NCEP)
expert panel on detection, evaluation, and
treatment of high blood cholesterol in
adults (Adult Treatment Panel [ATP] III)
(10,21). The diagnosis of MS was made
when subjects had three or more risk fac-
tors for MS. Subjects with zero to one and
two risk factors for MS were classiﬁed as
no MS and risk for developing MS, re-
spectively (Supplementary Table 1).
Measurements
Brachial systolic and diastolic BP (SBP and
DBP) were recorded in duplicate, with an
appropriately sized cuff, using a validated
oscillometric sphygmomanometer (Omron
HEM-705CP) (22), and values were pre-
sented as an average of two recordings.
BMI was calculated as weight (kg)/(height
[m])2. Waist and hip circumferences (cm)
were measured on a subject in a standing
position with feet 15 cm apart. Waist cir-
cumference was measured at themidpoint
between the iliac crest and lowest rib. Hip
circumference was measured at the mid-
point between the waist and groin. During
the measurement, the tape measure was
parallel to the ground.
Arterial stiffness was assessed by mea-
suring carotid-femoral PWV (CF-PWV),
as previously described (23), using the
SphygmoCor apparatus (SphygmoCor
BPAS-1; AtCor Medical, Sydney, Australia).
Central augmentation index (cAIx) was esti-
mated using the same system (23). Brachial
artery ﬂow-mediated dilation (FMD) was
used to assess endothelium-dependent vaso-
motor function as described elsewhere (24).
FMD was quantiﬁed as a percentage change
from baseline in brachial artery diameter after
5 min of forearm ischemia. Endothelium-
independent vasomotor function was as-
sessed using 25 mg nitroglycerine (NTG)
by sublingual administration (25).
Renal function assessment
Creatinine clearance, as an estimate of
glomerular ﬁltration rate (eGFR), was
calculated according to the Cockcroft and
Gault (C&G) equation (26): (140 2 age
[years] 3 weight [kg] 3 1.23 for male
or 1.05 for female)/serum creatinine
(mmol/L). The C&G equation was se-
lected to assess renal function in this
study because it is more accurate than
the Modiﬁcation of Diet in Renal Disease
(MDRD) equation when used to assess
mild renal insufﬁciency (27). It was fur-
ther corrected by body surface area.
Statistical analyses
Data were statistically analyzed using
SPSS program for Windows (SPSS 15.0;
SPSS Inc., Chicago, IL). Descriptive data
are given as mean 6 SD unless otherwise
stated. Means of the categorical data (sub-
jects without MS, subjects with risk of
developing MS, and subjects with MS)
were compared by one-way ANOVA.
Continuous data (risk factors for MS as
zero to ﬁve risk factors) were analyzed
by correlation coefﬁcients calculated us-
ing the Pearson method. Stepwise linear
regression was used for multivariate
analysis. A signiﬁcant level was taken as
P value ,0.05.
RESULTSdCKD patients (n = 113) and
age-matched non-CKD control subjects
(n = 23) were enrolled into the study. Base-
line characteristics of the studied subjects
are given in Supplementary Table 2.
Causes of CKD and medication used by
the patients are described in Supplemen-
tary Table 3.
Subjects were classiﬁed into three
categories according to the number of risk
factors for MS (see RESEARCH DESIGN AND
METHODS). Twenty-six subjects (19%) had
MS and 27 (20%) were deﬁned as at risk
for developing MS. All three categories
were comparable in respect to age and
eGFR. As expected, subjects with MS
had a higher BMI, waist circumference,
SBP, DBP, plasma glucose, and triglycer-
ides and lower HDL cholesterol compared
with those without MS or those at risk for
developing it (Table 1). With regard to the
relationship of the risk factors for MS to
renal function, only SBP increased as eGFR
declined (r2 =0.11;P,0.01);waist circum-
ference, DBP, plasma glucose, triglycerides,
and HDL cholesterol showed no
Table 1dRisk factors for MS, arterial stiffness, and endothelial function
No MS Risk for MS MS
N 83 27 26
Male/female (n) 50/33 18/9 20/6
Smoker/nonsmoker (n) 14/69 2/25 9/17
Age (years) 46 6 10 49 6 11 50 6 8
eGFR (mL/min/1.73 m2) 73 6 34 65 6 33 59 6 36
BMI (kg/m2)* 26 6 4 28 6 5 33 6 4
Risk factors for MS
Waist circumference (cm)* 90 6 11 96 6 13 111 6 12
SBP (mmHg)* 113 6 13 124 6 15 124 6 13
DBP (mmHg)* 72 6 10 76 6 8 76 6 8
Glucose (mmol/L)* 4.8 6 0.5 5.1 6 0.5 5.4 6 0.6
Triglycerides (mmol/L)* 1.1 6 0.4 1.4 6 0.8 2.4 6 1.2
HDL cholesterol (mmol/L)* 1.4 6 0.3 1.2 6 0.3 0.9 6 0.2
Arterial stiffness and endothelial
dysfunction
CF-PWV (m/s)* 6.4 6 1.0 7.0 6 1.4 7.5 6 1.7
cAIx (%) 22 6 13 22 6 13 25 6 11
FMD (%) 4.8 6 2.9 3.4 6 2.8 3.5 6 2.8
NTG (%) 12.4 6 5.2 10.6 6 4.1 10.2 6 4.6
No MS, subjects with zero to one risk factor for MS; risk for MS, subjects with two risk factors for MS; MS,
subjects with three or more risk factors for MS. *P , 0.05 for one-way ANOVA by MS groups.
care.diabetesjournals.org DIABETES CARE, VOLUME 35, AUGUST 2012 1775
Lilitkarntakul and Associates
relationship to renal function. CF-PWV
was higher in the MS group (Table 1 and
Fig. 1A and C) whereas cAIx showed no
relationship to MS (Table 1). FMD was
lower in the MS group and subjects at
risk for MS compared with those without
MS (Table 1 and Fig. 1B and D) but this
did not reach statistical signiﬁcance. The
endothelium-independent response to
NTG had no relationship to MS (Table 1).
Relationships and predictors of
arterial stiffness
Univariate analysis to assess the relation-
ship of CF-PWV to individual MS risk
factors, the number of MS risk factors,
and related parameters that are not in-
cluded in the National Cholesterol Edu-
cation Program (NCEP) ATP III criteria
(eGFR, age, BMI, and waist-to-hip ratio)
was performed. CF-PWV only correlated
with eGFR when all subjects were con-
sidered together (r2 = 0.07; P, 0.01) but
not when split into the three groups ac-
cording to the presence, risk, or absence
of MS (Fig. 1A). However, PWV in subjects
with MS was signiﬁcantly higher than in
subjects without MS (Fig. 1A and C).
With regard to the individual risk factors
for MS, CF-PWV increased with waist
circumference, waist-to-hip ratio, SBP,
and plasma glucose (Fig. 2A–D). Addition-
ally, CF-PWV correlated with age (r2 =
0.25; P , 0.01), BMI (r2 = 0.06; P ,
0.01), DBP (r2 = 0.07; P , 0.01), and
plasma triglycerides (r2 = 0.05; P , 0.05)
but not sex, smoking status, or HDL
cholesterol.
In multivariate analysis, when renal
function and conventional risk factors
were entered into the model, age and sex
were independent predictors of arterial
stiffness (Table 2, model 1). When either
the presence of MS or the number of risk
factors for MS that a subject had were
Figure 1dScatter and box plots showing associations between the number of the MS risk factors and CF-PWV (A and C) and FMD (B and D). No
MS (○, solid ﬁtted line), subjects without MS (zero to one risk factor); risk for MS (-, long-dashed ﬁtted line), subjects at risk for developing MS
(two risk factors); MS (4, short-dashed ﬁtted line), subjects with MS (three or more risk factors). P values are for one-way ANOVA (C and D).
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considered, both of them, together with age
and sex, independently predicted CF-PWV
(Table 2, models 2 and 3). When the indi-
vidual risk factors for MS were considered,
sex was replaced by waist circumference,
SBP, and DBP as independent predictors
of CF-PWV (Table 2, model 4).
Relationship and predictors of
endothelial dysfunction
In univariate analysis, FMD correlated
with eGFR when all subjects were con-
sidered together (r2 = 0.04; P , 0.05)
but not when subjects were divided into
the three MS groups. FMD did not change
according to the presence, risk, or absence
ofMS (Fig. 1B andD). FMD correlatedwith
waist circumference, waist-to-hip ratio, and
SBP but not plasma glucose (Fig. 2E–H).
Additionally FMD did not correlate with
age, BMI, DBP, plasma triglycerides, HDL
cholesterol, or smoking status.
In multivariate analysis assessing re-
nal function and conventional risk fac-
tors, eGFR was an independent predictor
of FMD (Table 2, model 1). Although the
presence or absence of MS did not predict
endothelial dysfunction, the number of
MS risk factors did (Table 2, models 2
and 3). When the risk factors for MS were
considered individually in the model, SBP
and DBP alone were independent predic-
tors of FMD (Table 2, model 4).
CONCLUSIONSdIn a cohort of sub-
jects withminimal comorbidity and an eGFR
ranging from 8 to 154 mL/min/1.73 m2,
wehavepreviously shown that renal function
is related to an increase in arterial stiffness
and endothelial dysfunction, as measured
by CF-PWV and FMD, respectively (4). We
now show that subjects in this cohort with
MS have increased arterial stiffness com-
pared with those without MS. Importantly,
this is independent of the level of renal func-
tion (eGFR). Both the presence of MS and
the number of MS risk factors are indepen-
dent predictors of arterial stiffness in this co-
hort. Furthermore, when risk factors for MS
were considered individually, waist circum-
ference and blood pressure were determi-
nants of arterial stiffness, independent of
renal function, age, sex, and smoking status.
Our study cohort was carefully se-
lected to have low comorbidity. Thus, the
prevalence of MS in this CKD population
is lower than previously reported in di-
alysis (19,28), hypertensive (15), and di-
abetic patients (16) but is comparable to
healthy subjects (18 vs. 10–19%) (14).
Interestingly, despite this selection bias
against MS and its risk factors, we have
Figure 2dScatter plots showing correlations between CF-PWV and waist circumference (A),
waist-to-hip ratio (B), SBP (C), and plasma glucose (D). Scatter plots showing correlations
between FMD and waist circumference (E), waist-to-hip ratio (F), SBP (G), and plasma glucose
(H). Male:-, dashed line; female: ○, solid line.
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shown that, irrespective of renal function,
there is an increase in arterial stiffness in
our subjects with MS or risk factors for
MS, and that these independently predict
arterial stiffness when considered along-
side conventional risk factors. This ﬁnd-
ing is in keeping with previous data from
healthy subjects (13,14,29,30), hyperten-
sive patients (15), and patients with dia-
betes (16).
Our data also show that waist circum-
ference is a predictor of arterial stiffness in
this population and this is independent
of renal function, age, BP, and sex. Our
analysis considered the whole cohort of
113 CKD patients and 23 age-matched,
non-CKD control subjects, but waist cir-
cumference remains an independent pre-
dictor of arterial stiffness when the CKD
patients are considered alone. This has
previously only been shown in hyperten-
sive patients (15). Obesity is associated
both with increased arterial stiffness (31)
and an increased risk of CVD (32). Our
data suggest that, in patients with CKD,
waist circumference, a marker of central
obesity, may be a better surrogate for arte-
rial stiffness than BMI or cholesterol sub-
types such as HDL cholesterol and
triglycerides.
In the current study, subjects withMS
did not have signiﬁcantly impaired endo-
thelial function compared with those
without MS, regardless of renal function.
This is similar to data from studies in
healthy subjects (33,34), those at risk for
developing diabetes (35,36), and those
with peripheral vascular disease (37).
However, in a study of ;1,000 elderly
subjects, including those with CVD and
diabetes, where endothelial function was
assessed using both an invasive forearm
technique and FMD (38), the former
showed signiﬁcantly impaired endothe-
lial function in the MS group. The inva-
sive forearm technique is considered to
assess vascular function of the resistance ar-
teries, whereas FMD is a measure of conduit
artery function. Thus, it is possible that MS
is associated with a predominant dysfunc-
tion of the resistance vessels and, hence, by
using FMD, we did not detect signiﬁcant
endothelial dysfunction in our study cohort.
We also observed no association between
the number of risk factors for MS and
FMD. This is in contrast to a previous study
in subjects at risk for developing diabetes
(36), but this may in part be explained by
genetic inﬂuences in diabetes (and insulin
resistance states) not currently considered
to be of importance in the majority of
CKD patients.
Of all the risk factors studied here,
conventional and MS related, only BP is
an independent predictor of endothelial
dysfunction (Table 2, model 4). This re-
sult both conﬁrms and contradicts those
of previous studies. Similar to our ﬁnd-
ings, Scuteri et al. (35) found BP (both
SBP and DBP) to be an independent pre-
dictor of endothelial dysfunction in nor-
moglycemic ﬁrst-degree relatives of
patients with diabetes. However, Kovaite
et al. (29) found this not to be the case
when studying 186 “asymptomatic sub-
jects without overt cardiovascular disease.”
Notably, one-third of subjects studied ful-
ﬁlled criteria for MS. A study in CKD has
shown that, similar to the current data, re-
nal function is a predictor of endothelial
dysfunction (39). However, this study
was performed in CKD patients with dia-
betes and this may act as a signiﬁcant con-
founder. Furthermore, in that study, an
invasive forearm technique measured en-
dothelial function in a different vascular
bed compared with the technique of FMD
used in the current study.
Interestingly, we found an inverse
association between DBP and CF-PWV
(Table 2) and a positive association be-
tween DBP and FMD (Table 2). However,
these may be explained by an effect of
pulse pressure, which is positively associ-
ated with CF-PWV and inversely related
to FMD, since both SBP and DBP were
entered into the analysis.
We recognize some limitations to the
current study. There are several criteria
for the diagnosis of MS (14). As our pa-
tients were not diabetic, we cannot use the
criteria proposed by the World Health
Organization and, therefore, the evaluation
of an effect of insulin resistance to arterial
stiffness and endothelial dysfunction is lim-
ited and does not allow data comparison
with other studies using World Health Or-
ganization criteria. Also, an increased girth
Table 2dMultivariate analysis of renal function, conventional cardiovascular risk factors,
and risk factors for MS, as independent predictors for CF-PWV and FMD
CF-PWV
Predictors Model 1 Model 2 Model 3 Model 4
eGFR 20.11 20.11 20.12 20.11
Age 0.52* 0.49* 0.47* 0.39*
Sex (male/female) 0.18† 0.15† 0.16† 0.01
Smoking status (yes/no) 20.09 20.14 20.10 20.03
Presence of MS (yes/no) d 0.20* d d
Number of MS risk factors (0–5) d d 0.23* d
Waist circumference d d d 0.24*
SBP d d d 0.53*
DBP d d d 20.27*
Plasma glucose d d d 0.03
Triglycerides d d d 0.06
HDL cholesterol d d d 20.09
r2 0.28* 0.31* 0.32* 0.48*
FMD
Predictors Model 1 Model 2 Model 3 Model 4
eGFR 0.02† 0.02† 0.18† 0.10
Age 20.10 20.10 20.07 20.05
Sex (male/female) 20.11 20.11 20.11 20.06
Smoking status (yes/no) 20.02 20.02 20.01 20.02
Presence of MS (yes/no) d 20.10 d d
Number of MS risk factors (0–5) d d 20.18† d
Waist circumference d d d 20.14
SBP d d d 20.50*
DBP d d d 0.28†
Plasma glucose d d d 20.02
Triglycerides d d d 20.05
HDL cholesterol d d d 0.08
r2 0.04† 0.04† 0.07† 0.12*
The table gives standard regression coefﬁcients (b values). *P , 0.01. †P , 0.05.
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has the potential to artifactually increase
the measurement entered for the distance
traveled by the pulse wave (compared with
the actual distance) in calculating PWV.
Thus, the reported PWV will be higher
than the “true” value. It is possible that this
is responsible, in part, for the higher PWV in
the MS group in this study. However, our
subjects were chosen because of low comor-
bidity and are not typical of “general” CKD
patients (including patients with diabetes)
particularly in their body habitus. Median
BMI was 26.9 kg/m2, and the patient with
the highest BMI did not have MS by ATP III
criteria. Additionally, the 54 patients whose
waist measurement was above the deﬁning
level for a risk factor for MS were spread
throughout the three groups: 16 patients
were in the “no MS” group, 17 in the “risk
of MS” group, and 21 in the “MS” group.
Some of the medications taken by our pa-
tients, such as angiotensin-converting
enzyme inhibitors, angiotensin receptor
blockers, b-blockers, and statins, may have
had effects on both CF-PWV and FMD.
However, all patients were stabilized on
their therapies and did not receive their
medications on the study day until after
measurements weremade. The low number
of smokers in this study may be responsible
for the lack of expected relationships be-
tween smoking status and both arterial
stiffness and endothelial dysfunction; al-
though when only the CKD patients are
considered in the multivariate analysis,
smoking is an independent predictor of
PWV in models 2 and 3. Finally, as this
was a cross-sectional study, we cannot fully
deﬁne the causal relationships behind the
associations described, though they do
have a sound mechanistic basis.
In summary, the current study shows
that, in the absence of CVD and diabetes
and irrespective of renal function, age,
smoking status, and sex, CKD patients
with MS have increased arterial stiffness
compared with those without MS but no
difference in endothelial function. Although
BP remains the strongest determinant of
both arterial stiffness and endothelial dys-
function, the presence of MS or its risk
factors is also an important determinant of
arterial stiffness in this CKD cohort. Impor-
tantly, waist circumference is an indepen-
dent predictor of arterial stiffness in this
cohort; hence, educationon lifestyle changes
and weight management interventions
offer a different therapeutic perspective,
complementary to drug management of
traditional cardiovascular risk factors, such
as hypertension and hypercholesterolemia,
that should not be overlooked in patient
care. Given these currently noncomorbid
patients in this cohort only had modest
increases in BMI, the early and aggressive
control of weight should be a focus for
intervention. As this is not related to
renal function, it provides an additional
target for therapies aimed at improving
cardiovascular outcomes at all stages of
CKD.
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